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Abstract 
Background: Nonalcoholic fatty liver diseases (NAFLD) is one of the main chronic liver diseases and raises the risk 
of morbidity and mortality due to its inevitable outcomes. Understanding the clinical manifestations of the liver is 
critical to identify NAFLD patients with the greatest risk of developing nonalcoholic steatohepatitis and cirrhosis. In 
the liver, C1q/TNF-related protein 1 (CTRP1) modulates both glucose and lipid metabolism and improves insulin 
sensitivity which may affect the pathologies of the liver. Materials and Methods: This study was conducted on 22 
patients with NAFLD confirmed by ultrasonography and 21 healthy subjects. Clinical and histological variables were 
analyzed. The ultrasonography procedure was used to quantity Common bile duct (CBD). Liver stiffness (LS) was 
measured by transient elastography. Results: There was a significant difference in CTRP1 levels between NAFLD 
patients and controls (p=0.032). Moreover, there was a significant positive correlation between CTRP1 level and 
liver enzymes including AST (r=0.667; p=0.001), ALT (r=0.433; p=0.044), and γ-GT (r=0.428; p=0.047) in NAFLD 
patients. There was also a significant positive correlation between CTRP1 level and CBD (r= 0.469; p=0.028) in 
NAFLD patients. Moreover, the largest CBD was measured as 5.99 mm. Conclusion: It seems that CTRP1 is a 
novel adipokine related to the pathogenesis of NAFLD and is associated with the clinical manifestations of the liver 
such as liver enzymes, and CBD.  
Keywords: Nonalcoholic fatty liver diseases (NAFLD), C1q/TNF-related protein 1 (CTRP1), Common bile duct 
(CBD), Liver stiffness (LS). 
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Nonalcoholic fatty liver disease (NAFLD) is 
recognized as one of the most prevalent liver diseases 
involving a great proportion of the general population. 
NAFLD is strongly related with the entire spectrum of 
metabolic-related diseases such as obesity, type two 
diabetes, and cardiovascular diseases [1]. Regarding 
many similar mechanism underlying metabolic 
disorders, the existence of common molecular 
regulators contributing to the incidence of these 
diseases is predictable. Rising evidence indicated the 
critical role of adipokines in the pathomechanism of 
NAFLD. Adipokines secreted by various tissues, 
particularly adipose, regulate several processes such as 
glucose and lipid metabolism [2]. Previous studies 
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indicated that Adipokines can regulate many biological 
processes involved in hepatic function, such as 
inflammation, angiogenesis, vasodilation, and 
deposition of fat. Therefore, these molecules are 
supposed to regulate disease severity in NAFLD 
patients. Subsequently, their serum levels may be 
correlated with parameters of hepatic function which 
are linked to the complications of such patients [3].  
Among these adipokines, C1q/TNF-related 
proteins (CTRPs) as recently recognized adipokines 
have an important role in energy homeostasis and 
diseases related to the liver [4]. CTRP1 as a novel 
metabolic hormone is a member of CTRPs family 
which is shown to have imperative roles in glucose and 
lipid metabolism. CTRP1 improves glucose and lipid 
oxidation, insulin sensitivity, and overall energy 
homeostasis [5]. Previous studies reported that an 
abnormal secretion of CTRP1 results in defects in 
energy homeostasis and following insulin resistance 
(IR) in different tissues, particularly in the liver. 
Moreover, it is indicated that CTRP1 declines the 
formation of plaques and induces the generation of 
aldosterone. Consequently, CTRP1 may be linked to 
the pathogenesis of NAFLD in various ways [6-8]. 
Clinical manifestations of the liver i.e. 
fibrosis, steatosis, and focal lesions along with the bile 
ducts measurement such as common bile duct (CBD) 
provide critical information about the greatest risk of 
developing nonalcoholic steatohepatitis and cirrhosis 
in patients with NAFLD [9]. Although there are several 
studies on the association of CTRP1 with metabolic 
characteristics in patients suffering from metabolic 
abnormalities, no study has been conducted on the 
association of this CTRP with CBD in NAFLD. 
Regarding the important role of CTRP1 as a 
novel adipokine related to the pathogenesis of NAFLD 
and its possible correlation with the clinical 
manifestations of the liver such as liver enzymes, liver 
stiffness (LS), and CBD, here, we aimed to examine 
such associations in NAFLD patients compared to 
healthy subjects in order to provide new information 
underlying the possible development of nonalcoholic 
steatohepatitis and cirrhosis in relation with the 
secretion of CTRP1 along with the changes in clinical 




Study Population. A total of 43 subjects 
including 22 with NAFLD and 21 healthy individuals 
aged 43–72 years participated in this study. The 
participants were recruited from who referred to 
Shariati Hospital from March 2012 until November 
2013. Ultrasonography was applied to diagnose 
NAFLD patients. This study was approved by the 
Ethics Committee of Tehran University of Medical 
Sciences (TUMS). Written informed consents were 
collected from all participants prior to the study. 
Participants were excluded if they had excessive 
alcohol consumption (> 30 g/d), or were diagnosed by 
severe related diseases such as viral hepatitis, 
hemochromatosis, autoimmune liver disease, and renal 
disease. Moreover, they were not eligible if had 
medication that caused steatosis including steroids, 
tamoxifen, estrogens, diltiazem, valproic acid, or 
methotrexate [5]. Liver ultrasound examination 
revealed the diameter of CBD and intrahepatic bile 
ducts due to the presence of a CBD stone. 
Anthropometric and laboratory 
measurements. Anthropometric indices of all 
participants including age, weight, height, and waist 
circumference (WC) were measured. Body mass index 
(BMI) was evaluated as body weight (kg) divided by 
the square of height (m2). Waist–hip ratio (WHR) was 
calculated according to the ratio of WC in cm divided 
by hip circumference in cm. For measuring the systolic 
and diastolic blood pressures, a manual 
sphygmomanometer was used.  
Biochemical and Laboratory Measurements. 
Serum was separated from blood samples collected 
from participants after overnight fasting. Blood 
samples were collected from all participants in EDTA-
containing tubes after overnight fasting. Next, blood 
samples were centrifuged for collection of plasma and 
stored at -80°C for the next analysis. Aspartateamino 
transferase (AST), alanine aminotransferase (ALT), 
and gamma-glutamyl transferase (γ-GT) were 
measured by auto analyzer using commercial kits (Pars 
Azmoon, Tehran, Iran). Any other biochemical 
parameters were analyzed by enzymatic process using 
assay kit adapted in hospitals. Homeostasis model 
assessment of IR (HOMA-IR) was calculated to 
recognize the insulin resistance (IR), using the 
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equation of fasting blood glucose (mg/dL) × fasting 
blood insulin (µU/mL) / 405. Adiponectin level was 
measured using the ELISA Kit (Elabscience, Wuhan, 
China) based on the manufacturer’s protocol. 
CTRP1 Measurement. CTRP1 levels were 
measured using an ELISA kit (Biovendor research and 
diagnostic products) with a minimum detectable 
concentration of 0.016 ng/ml, Intra assay Coefficients 
of Variability (CV) was 2.7% and Inter-assay CV was 
8.5%.  
LS measurement. LS was calculated using 
transient elastography by the FibroScan 502 machine 
(EchoSense, Paris, France, 5MHz). The M probe was 
applied for individuals with thoracic perimeter less 
than 110 cm and the XL probe for 110 cm and above, 
based on the manufacture’s protocol. The probe was 
placed on the subject’s skin, overlying the right lobe of 
the liver, through the intercostal spaces. Each subject 
had at least ten measurements and the median value 
was documented. With an inter-quartile range of less 
than 30 % of the median reading, values were regarded 
as valid. 
Statistical Analysis. Values were presented as 
mean ± standard error of mean (SEM). Normality was 
tested for all quantitative variables by means of the 
Shapiro-Wilk test. Independent student t-test was 
applied for the comparison of data between NAFLD 
and healthy participants. Pearson correlation analysis 
was done to assess the possible correlation between 
CTRP-1 and biochemical features. P-value of <0.05 
was considered statistically significant. SPSS 20 
(SPSS, Chicago, IL, USA) was applied to analyze the 
results. 
Results 
The clinical and laboratory characteristics of 
study participants are provided in Table 1. Based on 
the results, BMI (p=0.000), WHR (p= 0.000), 
creatinine (p=0,000), TG (p=0.019), ALT (p=0.001) γ-
GT (p=0.001), insulin (p=0.001), HOMA-IR 
(p=0.001), and LS (p=0.004) were significantly 
different among two groups. Mean value of CTRP1 
and adiponectin between two groups are depicted in fig 
1 and 2, respectively. The circulating levels of CTRP1 
and adiponectin were significantly different in the two 
groups (p<0.05). Indeed, the NAFLD group had a 
higher level of CTRP1 (p=0.032) and lower level of 
adiponectin (p=0.002) compared to the control group.  
 
 
Figure 1. Graphic representation of the circulating level of CTRP1 in 
NAFLD group compared to control group. Data was shown as mean ± 
standard error of mean (SEM). 






Healthy subjects  
0.448 51.84±6.32 52.96±8.34 Age, years 
0.003 132.57±19.40 120.33±21.22 SBP, mmHg 
0.002 84.20±13.82 75.31±13.89 DBP, mmHg 
0.000 28.58±3.68 23.90±4.7 BMI,  kg/m2 
0.000 0.99±0.03 0.93±0.07 WHR, - 



















0.147 23.68±9.41 21.41±5.58 AST, U/L 
0.001 28.76±17.33 19.39±7.82 ALT, U/L 





0.001 2.15±1.27 1.13±1.30 HOMA-IR, - 
0.004 5.18±1.78 4.08±1.21 LS, kPa 
0.812 4.52±1.44 4.61±1.38 CBD, mm 
*Correlation is significant at .05. Continuous variables with normal 
distribution were described as mean ± SEM. NAFLD, non-alcoholic fatty 
liver disease; SBP ,systolic blood pressure; DBP, diastolic blood pressure;  
BMI ,body mass index; WHR ,waist-to-hip ratio; FBG ,fasting blood 
glucose; TG, triglycerides; HDL- C, high-density lipoprotein cholesterol; 
LDL-C, low-density lipoprotein cholesterol; ALT ,alanine amino 
transferase; AST, aspartate amino transferase; ɤ-GT , gamma glutamyl 
transferase; LS ,liver stiffness; HOMA-IR, homeostasis model assessment 
of insulin resistance; CBD, common bile duct;  
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Figure 2. Graphic representation of the circulating level of adiponectin 
in NAFLD group compared to control group. Data was shown as mean 
± standard error of mean (SEM). 
We also analyzed the correlation between 
CTRP1 levels and liver enzymes including AST, ALT, 
γ-GT, insulin, HOMA-IR, LS, and CBD in the whole 
study population as provided in Table 2. We observed 
a significant positive correlation between CTRP1 level 
and liver enzymes including AST (r=0.667; p=0.001), 
ALT (r=0.433; p=0.044), and γ-GT (r=0.428; p=0.047) 
in NAFLD patients. There was also a significant 
positive correlation between CTRP1 level and CBD 
(r= 0.469; p=0.028) in NAFLD patients. 
 
Discussion 
The main finding of this study was a higher 
significant level of plasma CTRP1 in NAFLD patient 
compared to healthy subjects. Moreover, we measured 
the clinical manifestations of the liver of all 
participants including liver enzymes, LS, and CBD and 
their significant positive correlation with the 
circulating level of CTRP1. 
Chronic liver diseases such as NAFLD are 
reliable for developing hepatic fibrosis, cirrhosis, and 
hepatocellular carcinoma. NAFLD along with 
cholestatic liver diseases include a large number of 
conditions in which the damage is mainly focused on 
the liver and biliary system. These circumstances are 
linked to a specific pattern of chronic liver diseases 
focused on the bile ducts injury and are associated with 
biliary cirrhosis and liver failure [10].  
As the liver produces bile containing bile salts, 
cholesterol, and bilirubin, its disorders such as 
cirrhosis may contribute to the altered size of bile ducts 
from the liver to the gallbladder. In turn, bile duct 
obstructions may worsen chronic liver diseases, such 
as cirrhosis. Remarkably, people with liver and bile 
ducts disorders have a greater risk of developing 
related cancers [11-13]. Ultrasound imaging is a usual 
technique for the identification of biliary diseases 
which mostly occur in intrahepatic and extrahepatic 
biliary dilatation. The diameter of a common bile duct 
(CBD) is measured and recorded by this technique. 
Remarkably, some studies use sonography to measure 
the diameter changes of the CBD after 
cholecystectomy Based on available literature, the 
dilatation of the common bile duct seems to be helpful 
in distinguishing obstructive from non-obstructive 
causes of jaundice. Accordingly, it seems that 
increased level of CTRP1 act as a possible part in 
mediating CBD malstructure in NAFLD patients [14]. 
According to previous studies, the normal size of CBD 
is ranged between 4-12 mm with an average of 7.39 ± 
1.64 mm [15]. Moreover, the upper limit of normal for 
the CBD is regarded as 4–10 mm [16-18]. 
There is growing evidence suggesting the 
involvement of several factors including IR in the 
pathogenesis of NAFLD, however, it still needs further 
Table 2. The correlation of CTRP1 circulating levels with 
clinical manifestations of  the liver in healthy and NAFLD 
subjects. 
NAFLD subjects Healthy subjects  
r p r p CTRP1 
0.667 0.001 -0.008 0.973 AST, U/L 
0.433 0.044 -0.216 0.360 ALT, U/L 
0.428 0.047 0.237 0.302 γ-GT, U/L 
0.310 0.160 0.039 0.868 Insulin, µU/mL 
0.360 0.100 0.076 0.751 HOMA-IR, - 
0.296 0.204 0.175 0.444 LS, kPa 
0.469 0.028 0.073 0.753 CBD, mm 
*Correlation is significant at .05. NAFLD, non-alcoholic fatty liver 
disease; AST, aspartate amino transferase; ALT ,alanine amino 
transferase; ɤ-GT , gamma glutamyl transferase; LS ,liver stiffness; 
HOMA-IR, homeostasis model assessment of insulin resistance; CBD, 
common bile duct; CTRP1, C1q/TNF-related protein 1. 
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investigations [19-23]. Previous studies indicated that 
Adipokines can control different biological and 
molecular mechanisms involved in the hepatic 
function, such as inflammation, insulin sensitivity, and 
fat deposition [24-26]. Consequently, their circulating 
levels may propose correlations with parameters of 
hepatic clinical manifestations [3]. Among adipokines, 
CTRPs family, as a newly introduced family of 
adiponectin paralogs are important factors regulating 
energy homeostasis and IR [27-31]. However, their 
exact role in the pathogenesis of NAFLD, the related 
hepatic manifestations, and the following disposition 
of nonalcoholic steatohepatitis and cirrhosis have not 
been elucidated. In our recent study, we indicated the 
important role of CTRP1 in the pathogenesis of 
NAFLD with regulating glucose and lipid metabolism. 
Indeed, CTRP1 improves glucose and fatty acid 
oxidation and insulin sensitivity in tissues such as liver 
[5-8]. Nevertheless, the association between CTRP1 
and hepatic manifestations such as liver enzymes, LS, 
and CBD is not examined in previous studies and thus, 
the present study aimed to explore such associations in 
NAFLD patients compared to healthy subjects for the 
first time. 
Several studies indicated the higher 
circulating levels of CTRP1 in patients with type two 
diabetes, metabolic syndrome and coronary artery 
disease [32-34]. In contrast, it was reported that 
CTRP1 level was significantly decreased in diet-
induced obese mice which was correlated with 
improving the insulin sensitivity and decreasing the 
weight gain. It is stated that CTRP1 may decrease fat 
accumulation by enhancing fatty acid oxidation and 
energy expenditure through AMP-activated protein 
kinase (AMPK) activation, which stimulates 
mitochondrial fat oxidation. We propose several 
possibilities about the higher levels of CTRP1 and 
insulin together in the NAFLD patients compared to 
controls. First, it seems likely that the higher level of 
CTRP1 with a positive correlation with liver 
manifestations such as liver enzymes and CBD may be 
attributed to its compensatory role for improving 
insulin sensitivity. Second, it may also show CTRP1 
resistance in response to NAFLD development [5]. It 
should be noted that a higher expression of insulin, as 
a hallmark of IR, caused to fatty acid synthesis and 
accumulation in the liver [35]. Putting these together, 
CTRP1 may improve fat deposition and subsequent 
liver and bile duct damage through increasing insulin 
sensitivity.  
Furthermore, CTRP1 as a paralog of 
adiponectin, mediates some of its hepatoprotective 
functions, through compensating the action of 
adiponectin [35, 36]. This was supported by previous 
studies which indicated a higher level of CTRP1 in 
adiponectin-deficient mice [34, 37-40]. Since the 
adiponectin level was significantly lower in NAFLD 
patients compared to healthy subjects, the 
compensatory role of CTRP1 for loss of adiponectin 
may be considered here [41, 42].   
Conclusion 
Collectively, this study suggests the 
association between CTRP1 level and clinical 
manifestations of the liver i.e. hepatic enzymes 
including AST, ALT, and γ-GT and also CBD in 
NAFLD detection which provides new information 
underlying the possible development of nonalcoholic 
steatohepatitis and cirrhosis in patients with NAFLD. 
However, further investigations are required. 
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